Administrative/Regulatory
Apr. 13, 1999
Genentech to Pay for Leading a Growth Industry
SAN FRANCISCO - In what would be the largest federal criminal penalty paid for health-care fraud in Northern California, biotech giant Genentech is negotiating the final terms of a $50 million settlement to resolve allegations that it illegally marketed a synthetic human growth hormone for nine years for uses not approved by government regulators.
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In